Iambic Therapeutics, Inc. Form 424B4 — Oct 15, 2026
Iambic Therapeutics priced its IPO at $16.00 per share, offering 9,375,000 shares for gross proceeds of $150.0 million (approximately $135.0 million net), with underwriters holding a 30-day option on up to 1,406,250 additional shares. J.P. Morgan, Jefferies, BofA Securities, and Citigroup led the offering; ARK Investment Management and Duquesne Family Office indicated interest in up to $60.0 million combined.
Key figures
- Revenue
- 9426000
- Gross Proceeds
- 150000000
- Offering Price
- 16
- Shares Offered
- 9375000
- Net Proceeds
- 135000000
- Runway Guidance
- into or through Q4 2028
- Greenshoe Shares
- 1406250
- Reverse Split Ratio
- 1-for-5.2587
- Accumulated Deficit
- 245296000
- Cash As Of June30 2026
- 207878000
- Notes Conversion Shares
- 4949237
- Pro Forma Cash As Adjusted
- 409378000
- Proceeds Before Expenses
- 139500000
- Net Proceeds With Greenshoe
- 155900000
- Shares Outstanding Post IPO
- 47400796
- Total Capital Raised Pre IPO
- 461800000
- Underwriting Discount Total
- 10500000
- Convertible Notes Conversion
- 66500000
- Underwriting Discount Per Share
- 1.12
- Cornerstone Indications Of Interest
- 60000000
- Shares Outstanding Post IPOWith Greenshoe
- 48807046
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.